

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Review of TA263; Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

Final recommendation post consultation
The guidance should be transferred to the 'static guidance' list.

1. Background

This guidance was issued in August 2012.

At the GE meeting of 16 June 2015 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance' list.

3. Rationale for selecting this proposal

No significant new evidence has been identified that would be likely to change the current recommendation in TA263. It is therefore appropriate to transfer this guidance to the 'static guidance' list.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: Royal College of Pathologists</p> <p>Response to proposal: No comment</p>	<p>Comment from Technology Appraisals</p> <p>N/A</p>
<p>Respondent: Roche Products</p> <p>Response to proposal: No objection</p> <p>We have no objection to moving the above guidance to the static list as we agree with the assessment that no significant new evidence has been identified that would be likely to change the recommendation of the original guidance.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted.</p>
<p>Respondent: Pierre Fabre</p> <p>Response to proposal: Agree</p> <p>We have reviewed the original guidance and new clinical data published since the review and would agree with your original findings. Despite the new clinical data it would not be appropriate to allocate resource for a new Technological Appraisal.</p> <p>We support the NICE proposal that this guidance be transferred to the 'static guidance list'.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted.</p>

Paper signed off by: Helen Knight, 28 July 2015

Contributors to this paper:

Technical Lead: Chris Chesters

Project Manager: Andrew Kenyon